87 activities found

Webcast: mCRC患者の第三選択治療 - 選択、決定:ラウンドテーブルディベート

オンライン活動の目的はmCRC患者の治療のために、効果的な第三選択治療戦略を臨床医に提供することです。Clinic for Tumerbiologie(腫瘍生物学クリニック)のDirk Arnold医師がニューヨーク州メイヨ・クリニック、Axel Grothey医師とルーヴァン・カトリック大学Eric Van Cutsem医師で行われるラウンドテーブルディベートの司会をします。第二選択治療後も進行した、進行疾患患者の最適治療を促進する、第二選択療法戦略の利点と課題について検討していきます。
0.75 CME

Webcast: Tratamiento de tercera línea para pacientes con Cáncer colorrectal metastásico (CRCm) - Opciones y decisiones: Mesa de debate

Este intercambio en línea tiene como objetivo ofrecer a los médicos estrategias de tratamiento de tercera línea para tratar a sus pacientes con CRCm. El Dr. Dirk Arnold, de la clínica Klinik für Tumorbiologie, será el moderador del debate entre el Dr. Axel Grothey, de Mayo Clinic, y el Dr. Eric Van Cutsem, del Hospital de la Universidad de Leuven. Se evaluaron los beneficios y dificultades de posibles estrategias de terapia de tercera línea, que pueden ofrecer cuidados óptimos para pacientes con enfermedades avanzadas que tuvieron un progreso después de las dos primeras líneas de tratamiento.
0.75 CME

Expert Perspectives: Great Debates & Updates in Thoracic Malignancies 2015

In the past year, tremendous progress has been made in the management of thoracic malignancies with significant advances in radio-, immuno-, systemic, and targeted therapies. Because of several unresolved clinical issues and the rapid progress in clinical research in lung cancer, the most current information is not readily disseminated and discussed among the medical community, challenging lung cancer specialists to evaluate and interpret the clinical significance of emerging strategies. This online activity will summarize the most up-to-date and pertinent data presented during the Great Debates & Updates in Thoracic Malignancies conference, held in La Jolla, CA on July 25, 2015.
0.5 CME

Webcast: Strategies for Improving Shared Decision-making Regarding Neoadjuvant Therapy for HER2+ Breast Cancer

Oncologists have indicated that favorable data is not the only factor to consider in their treatment decisions related to use of HER2-targeted neoadjuvant therapy (NAC) in breast cancer. In fact, more than 40% of medical oncologists in the United States strongly believe, and rightly so, that NAC treatment decisions are not solely up to them. Rather, the decision to initiate NAC for breast cancer is best made using a shared decision making (SDM) approach with close cooperation between patients and their care team. This activity features a panel of breast cancer clinical experts, patient education specialists and navigators discussing best practices for multidisciplinary team-based SDM in breast cancer clinical care.
0.75 CME

Webcast: Tools and Resources for Improving Shared Decision-making Regarding Neoadjuvant Therapy for HER2+ Breast Cancer

Oncologists have indicated that favorable data is not the only factor to consider in their treatment decisions related to use of HER2-targeted neoadjuvant therapy (NAC) in breast cancer. In fact, more than 40% of medical oncologists in the United States strongly believe, and rightly so, that NAC treatment decisions are not solely up to them. Rather, the decision to initiate NAC for breast cancer is best made using a shared decision making (SDM) approach with close cooperation between patients and their care team. This activity features a panel of breast cancer clinical experts, patient education specialists and navigators discussing tools and resources that enhance SDM and multidisciplinary team-based care in breast cancer.
0.75 CME

Interactive Case: Enhancing Outcomes in mCRC with Angiogenesis Inhibitors

In the fourth e-learning activity of this 4-part series, Dr. Dirk Arnold discusses a patient case to illustrate best practices in the evidence-based use of angiogenesis inhibitors in metastatic colorectal cancer (mCRC).
0.5 CME

Webcast: Considerations for Pre-operative Therapy to Optimize Care of Women with HER2+ Breast Cancer

Use of human epidermal growth factor receptor 2 (HER2)-targeting agents is currently the therapy of choice in the adjuvant setting for HER2+ breast cancer; the desire to improve survival rates has led to its use in the neoadjuvant setting. Still, clinicians have contrasting perceptions of the value of neoadjuvant therapy in this setting, and may not effectively interpret the clinical significance of emerging data regarding such therapy, resulting in suboptimal care. This activity features Edibaldo Silva-Lopez, MD, a surgical oncologist from the University of Nebraska Medical Center in Omaha discussing key information that frames much of the current perception about and emerging evidence on this important clinical topic.
0.5 CME

Interactive Case: HER2+ BC Case 1: Potential Role of Neoadjuvant Therapy for a 30 yo Woman with T2 N1 BC

Use of human epidermal growth factor receptor 2 (HER2)-targeting agents is currently the therapy of choice in the adjuvant setting for HER2+ breast cancer; the desire to improve survival rates has led to its use in the neoadjuvant setting. Still, clinicians have contrasting perceptions of the value of neoadjuvant therapy in this setting, and may not effectively interpret the clinical significance of emerging data regarding such therapy, resulting in suboptimal care. To explore core clinical management challenges in this disease setting, this activity features a panel of 4 clinical experts from the disciplines of surgical oncology, clinical pathology, radiation oncology, and medical oncology using a tumor board format to discuss the case a 30-year-old African-American woman with a small HER2+ tumor in her left breast and a palpable L axillary node.
0.5 CME

Interactive Case: HER2+ BC Case 2: Potential Role of Neoadjuvant Therapy in a 56 yo Woman with T2 N0 ER+/PR+ BC

Use of human epidermal growth factor receptor 2 (HER2)-targeting agents is currently the therapy of choice in the adjuvant setting for HER2+ breast cancer; the desire to improve survival rates has led to its use in the neoadjuvant setting. Still, clinicians have contrasting perceptions of the value of neoadjuvant therapy in this setting, and may not effectively interpret the clinical significance of emerging data regarding such therapy, resulting in suboptimal care. To explore core clinical management challenges in this disease setting, this activity features a panel of 4 clinical experts from the disciplines of surgical oncology, clinical pathology, radiation oncology, and medical oncology using a tumor board format to discuss the case a 56-year-old woman who is postmenopausal and has a 3 cm breast tumor that is HER2+ and is estrogen receptor positive (ER+) and progesterone receptor positive (PR+).
0.5 CME

Interactive Case: HER2+ BC Case 3: Potential Role of Neoadjuvant Therapy in a 61 yo Woman with T2 N3 HER2+/ER-/PR- BC

Use of human epidermal growth factor receptor 2 (HER2)-targeting agents is currently the therapy of choice in the adjuvant setting for HER2+ breast cancer; the desire to improve survival rates has led to its use in the neoadjuvant setting. Still, clinicians have contrasting perceptions of the value of neoadjuvant therapy in this setting, and may not effectively interpret the clinical significance of emerging data regarding such therapy, resulting in suboptimal care. To explore core clinical management challenges in this disease setting, this activity features a panel of 4 clinical experts from the disciplines of surgical oncology, clinical pathology, radiation oncology, and medical oncology using a tumor board format to discuss the case a 61-year-old woman who is postmenopausal and has T2 N3 breast cancer that is HER2+ and is estrogen receptor negative (ER-) and progesterone receptor negative (PR-).